Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?

Chimeric Antigen Receptor (CAR) T-cell therapy has become a new therapeutic reality for refractory and relapsed leukemia patients and is also emerging as a potential therapeutic option in solid tumors. Viral vector-based CAR T-cells initially drove these successful efforts; however, high costs and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Magnani, Chiara F., Tettamanti, Sarah, Alberti, Gaia, Pisani, Ilaria, Biondi, Andrea, Serafini, Marta, Gaipa, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349235/
https://www.ncbi.nlm.nih.gov/pubmed/32471151
http://dx.doi.org/10.3390/cells9061337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349235/
https://www.ncbi.nlm.nih.gov/pubmed/32471151
http://dx.doi.org/10.3390/cells9061337

Ejemplares similares